Furthermore, MLH1 and MSH2 variants heralding Lynch syndrome or CMMRD syndrome are also considered actionable in a way of further surveillance and potential use of immune checkpoint inhibitors. The gene discussed is MSH2; the disease is Constitutional mismatch repair deficiency syndrome.